Teleflex Inks Collaboration Deal with FundamentalVR

Teleflex, a medical technologies company, has signed a collaboration agreement with FundamentalVR that focuses on accelerating the development of Teleflex’s UroLift 2 system for treatment of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate.

The UroLift 2 system is an updated version of the company’s UroLift system, which uses small implants to hold open the obstructed pathway that’s blocking urine flow.

UroLift 2 is currently FDA-cleared for use in the treatment of patients with benign prostatic hyperplasia, also known as enlarged prostate.

Under the agreement, FundamentalVR will provide Teleflex with its virtual reality training platform for users of the UroLift 2 system.

The financial terms of the collaboration agreement were not disclosed.